Wockhardt Limited, a subsidiary of the Wockhardt Group, is a pharmaceutical and biotechnology company headquartered in Mumbai, India providing affordable, high-quality medicines for a healthier world. The company was founded in 1960 by Habil Khorakiwala after Worli Chemical Works was acquired. It is India’s leading research-based global healthcare organization with manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.
European market generates more than 50% of its revenues. New and innovative business models have helped Wockhardt Limited make the most of emerging opportunities. The market presence has grown over time in emerging markets such as Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).
Wockhardt Limited is a MNC with a total of 8600 employees from 21 different countries. With 3 research centres & 12 manufacturing units, its businesses range from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.
|Traded as||NSE: WOCKPHARMA|
|Key people||Habil Khorakiwala (Chairman), Murtaza Khorakiwala (managing director), Huzaifa Khorakiwala (Executive Director)|
|Products||Formulations, Biopharmaceuticals, Nutrition products, Vaccines|
|Revenue||₹46.14 billion (US$730 million)|
|Number of employees||8,600|
|Subsidiaries||Wockhardt Biopharm Limited, Vinton Healthcare Limited, Wockhardt Infrastructure Development Limited, Wockhardt UK Holdings Limited, Wockhardt Bio AG and Wockhardt Europe Limited|